DOV Confident Of Bicifadine "Residual Value" For Pain After Phase III Failure
This article was originally published in Pharmaceutical Approvals Monthly
DOV's analysis of a failed Phase III trial of its non-opioid analgesic bicifadine for chronic low back pain could be used to modify future and ongoing studies for the indication, according to the company
You may also be interested in...
DOV Pharmaceuticals' second Phase III clinical trial for its chronic lower back pain agent bicifadine will enroll a limited patient population, the company announced May 22
DOV is discontinuing development of its GABA receptor agonist ocinaplon "due to an unacceptable rate of liver enzyme elevations," the firm says Oct. 28. Ocinaplon, which had been in development for generalized anxiety disorder, had experienced several clinical holds, the most recent occurring in August (1Pharmaceutical Approvals Monthly September 2005, p. 15). "DOV will select a follow-on candidate from one of the backup compounds in its preclinical program," the company says. The firm also confirmed plans to submit an NDA for use of its non-opioid analgesic bicifadine in chronic low back pain during the first half of 2007. Phase II studies in osteoarthritis and neuropathic pain are slated to begin in the fourth quarter of 2005; an acute pain sNDA is slated for the fourth quarter of 2007...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011